Reopening Laboratory Research at SMHS
Reopening Laboratory Research at SMHS
Augmenting the research portfolio and elevating its prominence through enhanced quality and impact.
These facilities offer a wide range of services, including cutting-edge technologies and high-end instrumentation coupled with technical support for research.
Coronavirus (COVID-19) Update: SMHS Research Re-Start PlansReopening Laboratory Research at SMHS
Plans for Reopening Laboratory Research at SMHS
Roster for SMHS Reopening Committees
Visit GW SMHS ON CAMPUS Policies and Guidelines website
Reopening Laboratory Research at SMHS
Moncef Slaoui, PhD, MBA, chief adviser for the COVID-19 vaccine development initiative Operation Warp Speed, visited GW on Oct. 21 to raise awareness for the national vaccine development efforts, encourage greater participation in the clinical trials and recognize GW for exceeding its enrollment goals for its vaccine trial.
The George Washington University announced today its participation in a Sanofi COVID-19 vaccine clinical trial. GW was selected as one of approximately 25 sites in the United States to launch a phase 2 study for its adjuvanted recombinant protein-based COVID-19 vaccine candidate.
Researchers at the George Washington University found that the majority of dermatology patients were comfortable with virtual visits as an alternative to in-person appointments.
